(MASS) 908 Devices - Overview

Sector: HealthcareIndustry: Medical Devices | Exchange NASDAQ (USA) | Currency USD | Market Cap: 230m | Total Return 29% in 12m

Stock Analyzers, Spectrometers, Monitoring, Devices
Total Rating 39
Risk 27
Buy Signal -1.51
Medical Devices -6.0
Health Care Equipment -2.9
Market Cap: 230m
Avg Trading Vol: 1.69M USD
ATR: 6.09%
Peers RS (IBD): 62.6
Risk 5d forecast
Volatility65.7%
Rel. Tail Risk-13.1%
Reward TTM
Sharpe Ratio0.81
Alpha35.63
Character TTM
Beta0.332
Beta Downside0.440
Drawdowns 3y
Max DD84.85%
CAGR/Max DD-0.15
EPS (Earnings per Share) EPS (Earnings per Share) of MASS over the last years for every Quarter: "2021-03": -0.22, "2021-06": -0.27, "2021-09": -0.19, "2021-12": -0.12, "2022-03": -0.3, "2022-06": -0.26, "2022-09": -0.2, "2022-12": -0.31, "2023-03": -0.39, "2023-06": -0.29, "2023-09": -0.22, "2023-12": -0.23, "2024-03": -0.33, "2024-06": -0.31, "2024-09": -0.845, "2024-12": -0.2803, "2025-03": -0.1867, "2025-06": -0.36, "2025-09": -0.41, "2025-12": 0.1,
EPS CAGR: 15.13%
EPS Trend: 5.9%
Last SUE: 0.75
Qual. Beats: 0
Revenue Revenue of MASS over the last years for every Quarter: 2021-03: 5.543, 2021-06: 8.277, 2021-09: 12.545, 2021-12: 15.841, 2022-03: 8.306, 2022-06: 11.106, 2022-09: 15.797, 2022-12: 11.643, 2023-03: 9.487, 2023-06: 12.094, 2023-09: 14.297, 2023-12: 14.351, 2024-03: 7.422, 2024-06: 11.462, 2024-09: 14.519, 2024-12: 18.82, 2025-03: 11.777, 2025-06: 13.035, 2025-09: 14.005, 2025-12: 17.38,
Rev. CAGR: 21.76%
Rev. Trend: 44.9%
Last SUE: 0.61
Qual. Beats: 0
Risks
Technicals: volatile
Description: MASS 908 Devices March 04, 2026

908 Devices Inc. (MASS) is a technology company specializing in compact mass spectrometry devices. The companys products serve diverse applications including life sciences research, bioprocessing, and forensics, a broad market within the analytical instruments sector.

Their product portfolio includes handheld and desktop mass spectrometers. The MX908 is a portable device for rapid material analysis, while the Rebel and Maverick are desktop and in-line analyzers, respectively, used in bioprocessing for real-time monitoring of cell cultures and other parameters. Bioprocessing is a key component of biopharmaceutical manufacturing, a growing industry.

Additional products like Maven and Trace C2 offer online monitoring and control for bioprocesses, and the ZipChip solution enhances mass spectrometry sample analysis. The company operates globally. Further research on ValueRay can provide more in-depth financial and operational insights into MASS.

Headlines to Watch Out For
  • Bioprocessing product adoption drives revenue growth
  • Handheld device sales to forensics markets expand
  • Research and development spending impacts profitability
  • Global economic conditions influence capital expenditure
  • Regulatory changes for analytical devices create market shifts
Piotroski VR‑10 (Strict, 0-10) 2.5
Net Income: 19.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.13 > 0.02 and ΔFCF/TA 6.38 > 1.0
NWC/Revenue: 196.6% < 20% (prev 149.2%; Δ 47.44% < -1%)
CFO/TA -0.12 > 3% & CFO -23.7m > Net Income 19.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.24 > 1.5 & < 3
Outstanding Shares: last quarter (38.9m) vs 12m ago 12.25% < -2%
Gross Margin: 50.58% > 18% (prev 0.52%; Δ 5.01k% > 0.5%)
Asset Turnover: 32.15% > 50% (prev 32.75%; Δ -0.59% > 0%)
Interest Coverage Ratio: -21.80 > 6 (EBITDA TTM -30.5m / Interest Expense TTM -1.60m)
Altman Z'' -6.41
A: 0.58 (Total Current Assets 144.6m - Total Current Liabilities 34.1m) / Total Assets 190.1m
B: -1.17 (Retained Earnings -223.3m / Total Assets 190.1m)
C: -0.20 (EBIT TTM -34.9m / Avg Total Assets 174.8m)
D: -4.81 (Book Value of Equity -223.2m / Total Liabilities 46.4m)
Altman-Z'' Score: -6.41 = D
Beneish M -3.05
DSRI: 0.83 (Receivables 11.3m/12.6m, Revenue 56.2m/52.2m)
GMI: 1.02 (GM 50.58% / 51.70%)
AQI: 0.67 (AQ_t 0.19 / AQ_t-1 0.29)
SGI: 1.08 (Revenue 56.2m / 52.2m)
TATA: 0.23 (NI 19.5m - CFO -23.7m) / TA 190.1m)
Beneish M-Score: -3.05 (Cap -4..+1) = AA
What is the price of MASS shares? As of March 31, 2026, the stock is trading at USD 5.78 with a total of 225,832 shares traded.
Over the past week, the price has changed by -5.40%, over one month by -16.23%, over three months by +8.44% and over the past year by +29.02%.
Is MASS a buy, sell or hold? 908 Devices has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy MASS.
  • StrongBuy: 3
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MASS price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 10 73%
Analysts Target Price 10 73%
MASS Fundamental Data Overview March 28, 2026
P/S = 4.0841
P/B = 1.5907
Revenue TTM = 56.2m USD
EBIT TTM = -34.9m USD
EBITDA TTM = -30.5m USD
Long Term Debt = 4.63m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.7m USD (from shortTermDebt, last quarter)
Debt = 4.63m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -65.9m USD (from netDebt column, last quarter)
Enterprise Value = 121.2m USD (229.5m + Debt 4.63m - CCE 113.0m)
Interest Coverage Ratio = -21.80 (Ebit TTM -34.9m / Interest Expense TTM -1.60m)
EV/FCF = -4.92x (Enterprise Value 121.2m / FCF TTM -24.6m)
FCF Yield = -20.34% (FCF TTM -24.6m / Enterprise Value 121.2m)
FCF Margin = -43.85% (FCF TTM -24.6m / Revenue TTM 56.2m)
Net Margin = 34.69% (Net Income TTM 19.5m / Revenue TTM 56.2m)
Gross Margin = 50.58% ((Revenue TTM 56.2m - Cost of Revenue TTM 27.8m) / Revenue TTM)
Gross Margin QoQ = 52.67% (prev 52.52%)
Tobins Q-Ratio = 0.64 (Enterprise Value 121.2m / Total Assets 190.1m)
 Interest Expense / Debt = -34.64% (Interest Expense -1.60m / Debt 4.63m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -27.6m (EBIT -34.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.24 (Total Current Assets 144.6m / Total Current Liabilities 34.1m)
Debt / Equity = 0.03 (Debt 4.63m / totalStockholderEquity, last quarter 143.7m)
 Debt / EBITDA = 2.16 (negative EBITDA) (Net Debt -65.9m / EBITDA -30.5m)
 Debt / FCF = 2.67 (negative FCF - burning cash) (Net Debt -65.9m / FCF TTM -24.6m)
 Total Stockholder Equity = 147.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.15% (Net Income 19.5m / Total Assets 190.1m)
RoE = 13.25% (Net Income TTM 19.5m / Total Stockholder Equity 147.1m)
RoCE = -23.04% (EBIT -34.9m / Capital Employed (Equity 147.1m + L.T.Debt 4.63m))
 RoIC = -18.77% (negative operating profit) (NOPAT -27.6m / Invested Capital 147.1m)
 WACC = 7.01% (E(229.5m)/V(234.1m) * Re(7.15%) + (debt cost/tax rate unavailable))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 9.53%
 [DCF] Fair Price = unknown (Cash Flow -24.6m)
 EPS Correlation: 5.89 | EPS CAGR: 15.13% | SUE: 0.75 | # QB: 0
Revenue Correlation: 44.88 | Revenue CAGR: 21.76% | SUE: 0.61 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.14 | Chg7d=-0.075 | Chg30d=-0.075 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=-0.41 | Chg7d=-0.145 | Chg30d=-0.145 | Revisions Net=-1 | Growth EPS=-92.2% | Growth Revenue=+17.3%
EPS next Year (2027-12-31): EPS=-0.29 | Chg7d=-0.295 | Chg30d=-0.295 | Revisions Net=+0 | Growth EPS=+27.2% | Growth Revenue=+18.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
Additional Sources for MASS Stock Fund Manager Positions: Dataroma · Stockcircle